PREVENT and Consortia Project Results Presented at the AACR Annual Meeting 2019

Date Posted: 

Friday, March 15, 2019

NCI participated in the American Association for Cancer Research (AACR) Annual Meeting, held March 29–April 3, 2019, at Georgia World Congress Center in Atlanta, GA, including presenting the following research results from PREVENT- and Consortia-supported projects outlined below.

The PREVENT Cancer Preclinical Drug Development Program (PREVENT) is a peer-reviewed program designed to support development of the best ideas in cancer prevention using National Cancer Institute contract resources. The program is a pipeline that focuses on unmet needs in prevention that are not adequately addressed by the private sector. NCI actively partners with successful applicants to help them move their novel cancer preventive chemical or biological agents (singly or in combination) and biomarkers from the lab bench towards IND filing, proof-of principle clinical testing and registration or validation.

The Division of Cancer Prevention conducts systematic early clinical development of promising preventive agents through its Phase 0/I/II Cancer Prevention Clinical Trials Program, also known as the Consortia for Early Phase Prevention Trials. Cancer prevention drug discovery is identifying many new agents, including an increasing number of agents that intervene in specific molecular pathways thought to be critical to cancer development. Since cancer prevention studies focus on high-risk populations that do not necessarily harbor a detectable cancer, these studies require extensive biomarker analysis, investigation of the biologic effects of the cancer preventive agents on their intended molecular targets, and correlation with clinically relevant endpoints.

PREVENT-funded Project Presentations

Sunday, Mar 31, 2019

1:00 pm – 5:00 pm
Session Type: Poster Session
Session Category: Prevention Research
Session Title: Experimental Models and Biomarkers in Cancer Prevention Research
Location: Exhibit Hall B, Poster Section 28

647 / 4—Immunoprevention of triple negative breast cancer by a TOP2A multi-peptide vaccine
Sang Beom Lee1, Jing Pan1, Yueqiang Jiang1, Katie Palen1, Bryon Johnson1, Romaine Ingrid Fernando2, Shizuko Sei2, Ronald Lubet2, Ming You1, Yian Wang1. 1Medical College of Wisconsin, Milwaukee, WI; 2National Cancer Institute, Division of Cancer Prevention, Bethesda, MD.

648 / 5—Effects of bazedoxifene and lapatinib in the prevention of estrogen receptor positive (ER+) and negative (ER−) mammary cancers
Clinton J. Grubbs1, Altaf Mohammed2, Shizuko Sei2, Robert H. Shoemaker2. 1University of Alabama Comp. Cancer Center, Birmingham, AL; 2National Cancer Institute, Rockville, MD.

Monday, April 1, 2019

3:00 pm − 5:00 pm
Session Type: Mini-symposium
Session Category: Prevention Research
Session Title: Molecular and Cellular Mechanisms in Cancer Prevention Research
Location: Room A315 - Georgia World CC

2730 — Exceptional activity of ARN-509 (apalutamide) in prostate cancer prevention in rats
Genoveva Murillo1, Xinjian Peng1, Miguel Muzzio1, Maarten C. Bosland2, Elizabeth R. Glaze3, Chen Suen3, David L. McCormick1. 1IIT Research Institute, Chicago, IL; 2University of Illinois at Chicago, Chicago, IL; 3National Cancer Institute, Bethesda, MD.

2732 — Frameshift neoantigen vaccination prevent Lynch syndrome mouse model intestinal cancer
Ozkan Gelincik1, Hamza Ibrahim1, Mine Ozkan2, Aysel Ahadova2, Shizuko Sei3, Robert Shoemaker3, Mattias Kloor2, Magnus Von Knebel Doeberitz2, Steven M. Lipkin1. 1Weill Cornell Medical College in New York City, New York, NY; 2DKFZ, Heidelberg, Germany; 3NCI Division of Cancer Prevention, Rockville, MD.

Tuesday, April 2, 2019

8:00am − 12:00pm
Session Category: Late-breaking poster session
[Abstract text will be posted at 3:00 pm ET on Friday, March 29]
Session Title: Late-breaking research: Immunology 2
Location: Section 42

LB-200 / 18—A cGMP-grade chimeric papillomavirus candidate vaccine (HPV16 RG1-VLP) confers long‑term cross-protection compared to a nonavalent hpv vaccine in a pre-clinical papillomavirus animal model
Jiafen Hu1, Karla Balogh1, Ken Matsui2, Huimin Tan2, Pola Olczak2, George Buchman3, Brian Howard3, Jonathan White4, Michelle Kennedy4, Shizuko Sei5, Elizabeth Glaze5, Sarah Brendle1, Christina Schellenbacher6, Reinhard Kirnbauer6, Richard Roden7, Robert Shoemaker5, Neil Christensen1, Joshua Weiyuan Wang7. 1Pennsylvania State University, Hershey, PA; 2PathoVax LLC, Baltimore, MD; 3Paragon Bioservices, Baltimore, MD; 4MRIGlobal, Kansas City, MO; 5National Cancer Institute, Bethesda, MD; 6Medical University of Vienna, Vienna, Austria; 7Johns Hopkins, Baltimore, MD.

Wednesday, April 3, 2019

8:00 am − 12:00 pm
Session Type: Poster Session
Session Category: Prevention Research
Session Title: Cancer Chemoprevention and Interception: From Mechanism to Translation
Location: Exhibit Hall B, Poster Section 27

5065 / 3 — Pharmacological modulation of inflammation and p53 signaling synergize to prevents muscle invasive bladder cancer in-vivo
Venkateshwar Madka1, Yuting Zhang1, Nandini Kumar1, Gopal Pathuri1, Nicole Stratton1, Stanley Lightfoot1, Adam S. Asch1, Vernon E. Steele2, Altaf Mohammed2, Chinthalapally V. Rao1. 1University of Oklahoma Health Sciences Center, Oklahoma City, OK; 2National Cancer Institute, Rockville, MD.

5072 / 10 — Targeting the mTOR/TORC Pathway for the prevention of er-negative and triple-negative breast cancer
Abhijit Mazumdar, Jamal Hill, Yun Zhang, Lakshmi Reddy Bollu, Alejandro Contreras, Michelle Savage, Shizuko Sei, Altaf Mohammed, Powel Brown. UT MD Anderson Cancer Center, Houston, TX.

5074 / 12 — Optimizing erlotinib plus sulindac dosing regimens in a preclinical model of FAP Ahmetmursel Ulusan1, Praveen Rajendran1, Wan-Mohaiza Dashwood1, Altaf Mohammed2, Shizuko Sei2, Powel H. Brown3, Eduardo Vilar-Sanchez3, Roderick H. Dashwood1. 1Texas A&M College of Medicine, Houston, TX; 2National Cancer Institute (NCI), Rockville, MD; 3University of Texas MD Anderson Cancer Center, Houston, TX.

5075 / 13 — Naproxen blocks spontaneous lung adenoma progression to adenocarcinoma in Kras-G12V mice
Gaurav Kumar1, Venkateshwar Madka1, Craig Logsdon2, Anil Singh1, Nicole Stratton1, Stanley Lightfoot1, Altaf Mohammed3, Chinthalapally V. Rao1. 1Universotu of Oklahoma Health Sciences Center, Oklahoma City, OK; 2The University of Texas MD Anderson Cancer Center, Houston, TX; 3National Cancer Institute, Rockville, MD.

5079 / 17 — Targeting cholecystokinin-2 receptor (CCK2R) for pancreatic ductal adenocarcinoma prevention in p48Cre/+-LSL-KrasG12D/+ mice model
Altaf Mohammed1, Naveena B. Janakiram2, Chen Suen1, Nicole Stratton2, Stanley Lightfoot2, Anil Singh2, Gopal Pathuri2, Rebekah Ritchie2, Venkateshwar Madka2, Chinthalapally V. Rao2. 1National Cancer Institute, Rockville, MD; 2University of Oklahoma Health Sciences Center, Oklahoma City, OK.

5090 / 28 — Epitope mapping of mouse TERT for vaccine development
Yurong Song1, Jason Marshall1, Travis Kerr1, Ligia Pinto1, Shizuko Sei2, Robert Shoemaker2. 1Leidos Biomedical Research, Inc., Frederick, MD; 2National Cancer Institute, Bethesda, MD.

DCP-funded Clinical Project Presentations

Tuesday, April 2, 2019

1:00 pm − 5:00 pm
Session Type: Poster Session
Session Category: Clinical Trials
Session Title: Phase I-III Trials in Progress Part 3
Location: Exhibit Hall B, Poster Section 17

CT222 / 16 — A pilot study of a MUC1 vaccine in current and former smokers at high risk for lung cancer
Olivera J. Finn1, Julie Ward1, Tami Krpata2, Lisa Bengtson3, John McKolanis1, Sharon Kaufman2, Colleen Akerley2, April Felt2, Karrie Fursa2, Anne Holland4, Nathan Foster4, Andres Salazar5, Malgorzata Wojtowicz3, Eva Szabo3, Paul Limburg2, David Midthun2, Arjun Pennathur1. 1University of Pittsburgh School of Medicine, Pittsburgh, PA; 2The Mayo Clinic, Rochester, MN; 3Division of Cancer Prevention, NCI, Bethesda, MD; 4The Mayo Clinic, Rochester, PA; 5Oncovir, Inc., Washington, DC.

Tuesday, April 2, 2019

4:05 pm − 4:20 pm
Session Type: Clinical Trials Minisymposium
Session Category: Clinical Trials
Session Title: Developmental Therapeutics: Clinical Results of Novel Agents
Location: Marcus Auditorium- Bldg A-GWCC

CT236 — Randomized, double-blind, placebo-controlled trial of preventative MUC1 vaccine in patients with newly diagnosed advanced adenomas: Results from one-year booster
Olivera J. Finn1, Lisa Boardman2, Marcia Cruz-Correa3, Ajay Bansal4, David Kastenberg5, Chin Hurr6, Sharon Kaufman2, Colleen Akerley2, Lynda Dzubinski1, April Felt2, Karrie Fursa2, L.M. Rodriguez7, Ellen Richmond8, Asad Umar7, Eva Szabo7, John McKolanis1, Ryan McMurray2, Nathan Foster2, Andres Salazar9, Paul Limburg2, Robert Schoen1. 1University of Pittsburgh School of Medicine, Pittsburgh, PA; 2The Mayo Clinic, Rochester, MN; 3University of Puerto Rico, San Juan, PR; 4University of Kansas Medical Center, Kansas City, KS; 5Thomas Jefferson University, Philadelphia, PA; 6Massachusetts General Hospital, Boston, MA; 7Division of Cancer Prevention, NCI, Bethesda, MD; 8Uniformed Services University of the Health Sciences, Bethesda, MD; 9Oncovir, Inc., Washington, DC.

Other Presentations of Interest

Wednesday, April 3, 2019

8:00 am − 12:00 pm
Session Type: Poster Session
Session Category: Prevention Research
Session Title: Cancer Chemoprevention and Interception: From Mechanism to Translation
Location: Exhibit Hall B, Poster Section 27

5092 /30 — Participant satisfaction with cancer chemoprevention clinical trials: The Mayo Clinic Cancer Prevention Network (CPN) experience
David Zahrieh1, Ryan P. McMurray1, Nathan R. Foster1, Paul J. Limburg2, Sumithra J. Mandrekar1. 1Mayo Clinic, Rochester, MN; 2Mayo Clinic College of Medicine, Rochester, MN.

Wednesday, April 3, 2019

10:39 am − 10:51 am
Session Type: NCI/NIH Sponsored Session
Session Title: NCI Supported Biospecimen Resources Available to the Cancer Research Community
Location: Room A406 - Georgia World CC

Biospecimen resources available through the NCI’s Division of Cancer Prevention
Lori M. Minasian. National Cancer Institute, Rockville, MD.


Last updated: October 24, 2019